New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT07003295
Summary
This study is testing a two-drug combination (glofitamab and obinutuzumab) for adults with mantle cell lymphoma, a type of blood cancer, that has come back or stopped responding to a previous advanced treatment called CAR T-cell therapy. The main goal is to see if this new approach is safe and can shrink or eliminate the cancer. Researchers will give the drugs through an IV for up to 12 cycles and monitor patients for two years to track their response and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
JHU Sidney Kimmel Comprehensive Cancer Center LAO
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.